O	0	6	Impact
O	7	9	of
B-intervention	10	17	CYP19A1
I-intervention	18	21	and
I-intervention	22	26	ESR1
O	27	35	variants
O	36	38	on
B-condition	39	44	early
I-condition	44	45	-
I-condition	45	50	onset
I-condition	51	55	side
I-condition	56	63	effects
O	64	70	during
O	71	79	combined
O	80	89	endocrine
O	90	97	therapy
O	98	100	in
O	101	104	the
O	105	109	TEXT
O	110	115	trial
O	115	116	.

O	117	123	Single
O	124	134	nucleotide
O	135	148	polymorphisms
O	149	150	(
O	150	154	SNPs
O	154	155	)
O	156	158	in
O	159	162	the
O	163	171	estrogen
O	172	180	receptor
O	181	182	1
O	183	184	(
O	184	188	ESR1
O	188	189	)
O	190	193	and
O	194	204	cytochrome
O	205	209	P450
O	210	214	19A1
O	215	216	(
O	216	223	CYP19A1
O	223	224	)
O	225	230	genes
O	231	235	have
O	236	240	been
O	241	251	associated
O	252	256	with
O	257	263	breast
O	264	270	cancer
O	271	275	risk
O	275	276	,
O	277	286	endocrine
O	287	294	therapy
O	295	303	response
O	304	307	and
O	308	312	side
O	313	320	effects
O	320	321	,
O	322	328	mainly
O	329	331	in
O	332	346	postmenopausal
O	347	352	women
O	353	357	with
O	358	363	early
O	364	370	breast
O	371	377	cancer
O	377	378	.

O	379	383	This
O	384	392	analysis
O	393	398	aimed
O	399	401	to
O	402	408	assess
O	409	412	the
O	413	424	association
O	425	427	of
O	428	436	selected
O	437	445	germline
O	446	453	CYP19A1
O	454	457	and
O	458	462	ESR1
O	463	467	SNPs
O	468	472	with
O	473	478	early
O	478	479	-
O	479	484	onset
O	485	488	hot
O	489	496	flashes
O	496	497	,
O	498	506	sweating
O	507	510	and
O	511	526	musculoskeletal
O	527	535	symptoms
O	536	538	in
O	539	552	premenopausal
O	553	561	patients
O	562	570	enrolled
O	571	573	in
O	574	577	the
O	578	587	Tamoxifen
O	588	591	and
O	592	602	Exemestane
O	603	608	Trial
O	609	610	(
O	610	614	TEXT
O	614	615	)
O	615	616	.

O	617	622	Blood
O	623	626	was
O	627	636	collected
O	637	641	from
O	642	652	consenting
B-eligibility	653	666	premenopausal
I-eligibility	667	672	women
I-eligibility	673	677	with
I-eligibility	678	685	hormone
I-eligibility	685	686	-
I-eligibility	686	696	responsive
I-eligibility	697	702	early
I-eligibility	703	709	breast
I-eligibility	710	716	cancer
O	716	717	,
O	718	726	randomly
O	727	735	assigned
O	736	738	to
O	739	740	5
O	740	741	-
O	741	746	years
O	747	749	of
O	750	759	tamoxifen
O	760	764	plus
O	765	772	ovarian
O	773	784	suppression
O	785	786	(
O	786	789	OFS
O	789	790	)
O	791	793	or
O	794	804	exemestane
O	805	809	plus
O	810	813	OFS
O	813	814	.

O	815	818	DNA
O	819	822	was
O	823	832	extracted
O	833	837	with
O	838	844	QIAamp
O	845	849	kits
O	850	853	and
O	854	863	genotyped
O	864	867	for
O	868	871	two
O	872	879	CYP19A1
O	880	881	(
O	881	887	rs4646
O	888	891	and
O	892	899	rs10046
O	899	900	)
O	901	904	and
O	905	910	three
O	911	915	ESR1
O	916	917	(
O	917	926	rs2077647
O	926	927	,
O	928	937	rs2234693
O	938	941	and
O	942	951	rs9340799
O	951	952	)
O	953	957	SNPs
O	958	960	by
O	961	962	a
O	963	967	real
O	967	968	-
O	968	972	time
O	973	987	pyrosequencing
O	988	997	technique
O	997	998	.

O	999	1006	Adverse
O	1007	1013	events
O	1014	1015	(
O	1015	1018	AEs
O	1018	1019	)
O	1020	1024	were
O	1025	1033	recorded
O	1034	1036	at
O	1037	1045	baseline
O	1046	1049	and
O	1050	1051	3
O	1051	1052	-
O	1052	1059	monthly
O	1060	1066	during
O	1067	1070	the
O	1071	1076	first
O	1077	1081	year
O	1081	1082	.

O	1083	1095	Associations
O	1096	1098	of
O	1099	1102	the
O	1103	1111	genotype
O	1112	1120	variants
O	1121	1125	with
O	1126	1131	grade
O	1132	1133	≥
O	1133	1134	2
O	1135	1140	early
O	1140	1141	-
O	1141	1146	onset
O	1147	1155	targeted
O	1156	1159	AEs
O	1160	1162	of
O	1163	1166	hot
O	1167	1174	flashes
O	1174	1175	/
O	1175	1183	sweating
O	1184	1186	or
O	1187	1202	musculoskeletal
O	1203	1209	events
O	1210	1214	were
O	1215	1223	assessed
O	1224	1229	using
O	1230	1238	logistic
O	1239	1249	regression
O	1250	1256	models
O	1256	1257	.

O	1258	1263	There
O	1264	1268	were
B-total-participants	1269	1273	2660
O	1274	1287	premenopausal
O	1288	1296	patients
O	1297	1301	with
O	1302	1308	breast
O	1309	1315	cancer
O	1316	1318	in
O	1319	1322	the
O	1323	1332	intention
O	1332	1333	-
O	1333	1335	to
O	1335	1336	-
O	1336	1341	treat
O	1342	1352	population
O	1353	1355	of
O	1356	1360	TEXT
O	1360	1361	,
O	1362	1365	and
B-total-participants	1366	1370	1967
O	1371	1372	(
O	1372	1374	74
O	1375	1376	%
O	1376	1377	)
O	1378	1381	are
O	1382	1390	included
O	1391	1393	in
O	1394	1398	this
O	1399	1412	translational
O	1413	1418	study
O	1418	1419	.

O	1420	1423	The
O	1424	1431	CYP19A1
O	1432	1439	rs10046
O	1440	1447	variant
O	1448	1449	T
O	1449	1450	/
O	1450	1451	T
O	1451	1452	,
O	1453	1464	represented
O	1465	1467	in
O	1468	1470	23
O	1471	1472	%
O	1473	1475	of
O	1476	1481	women
O	1481	1482	,
O	1483	1486	was
O	1487	1497	associated
O	1498	1502	with
O	1503	1504	a
O	1505	1512	reduced
B-outcome	1513	1522	incidence
I-outcome	1523	1525	of
I-outcome	1526	1531	grade
I-outcome	1532	1533	≥
I-outcome	1533	1534	2
I-outcome	1535	1538	hot
I-outcome	1539	1546	flashes
I-outcome	1546	1547	/
I-outcome	1547	1555	sweating
O	1556	1557	(
O	1557	1567	univariate
O	1568	1572	odds
O	1573	1578	ratio
O	1579	1580	(
O	1580	1582	OR
O	1582	1583	)
O	1584	1585	=
O	1586	1587	0
O	1587	1588	.
O	1588	1590	78
O	1590	1591	;
O	1592	1594	95
O	1595	1596	%
O	1597	1599	CI
O	1600	1601	0
O	1601	1602	.
O	1602	1604	63
O	1604	1605	-
O	1605	1606	0
O	1606	1607	.
O	1607	1609	97
O	1609	1610	;
O	1611	1612	P
O	1613	1614	=
O	1615	1616	0
O	1616	1617	.
O	1617	1619	03
O	1619	1620	)
O	1620	1621	,
O	1622	1626	more
O	1627	1635	strongly
O	1636	1638	in
O	1639	1647	patients
O	1648	1656	assigned
O	1657	1667	exemestane
O	1668	1669	+
O	1670	1673	OFS
O	1674	1675	(
O	1675	1677	TT
O	1678	1680	vs
O	1681	1683	CT
O	1683	1684	/
O	1684	1686	CC
O	1686	1687	:
O	1688	1690	OR
O	1691	1692	=
O	1693	1694	0
O	1694	1695	.
O	1695	1697	65
O	1697	1698	,
O	1699	1701	95
O	1702	1703	%
O	1704	1706	CI
O	1707	1708	=
O	1709	1710	0
O	1710	1711	.
O	1711	1713	48
O	1713	1714	-
O	1714	1715	0
O	1715	1716	.
O	1716	1718	89
O	1718	1719	)
O	1720	1724	than
O	1725	1733	assigned
O	1734	1743	tamoxifen
O	1744	1745	+
O	1746	1749	OFS
O	1750	1751	(
O	1751	1753	OR
O	1754	1755	=
O	1756	1757	0
O	1757	1758	.
O	1758	1760	94
O	1760	1761	,
O	1762	1764	95
O	1765	1766	%
O	1767	1769	CI
O	1770	1771	=
O	1772	1773	0
O	1773	1774	.
O	1774	1776	69
O	1776	1777	-
O	1777	1778	1
O	1778	1779	.
O	1779	1781	27
O	1781	1782	,
O	1783	1794	interaction
O	1795	1796	P
O	1797	1798	=
O	1799	1800	0
O	1800	1801	.
O	1801	1803	03
O	1803	1804	)
O	1804	1805	.

O	1806	1808	No
O	1809	1820	association
O	1821	1825	with
O	1826	1829	any
O	1830	1832	of
O	1833	1836	the
O	1837	1844	CYP19A1
O	1844	1845	/
O	1845	1849	ESR1
O	1850	1859	genotypes
O	1860	1863	and
O	1864	1879	musculoskeletal
B-outcome	1880	1883	AEs
O	1884	1887	was
O	1888	1893	found
O	1893	1894	.

O	1895	1898	The
O	1899	1906	CYP19A1
O	1907	1914	rs10046
O	1915	1922	variant
O	1923	1924	T
O	1924	1925	/
O	1925	1926	T
O	1927	1933	favors
O	1934	1939	lower
B-outcome	1940	1949	incidence
I-outcome	1950	1952	of
I-outcome	1953	1956	hot
I-outcome	1957	1964	flashes
I-outcome	1964	1965	/
I-outcome	1965	1973	sweating
O	1974	1979	under
O	1980	1990	exemestane
O	1991	1992	+
O	1993	1996	OFS
O	1997	2006	treatment
O	2006	2007	,
O	2008	2018	suggesting
O	2019	2028	endocrine
O	2028	2029	-
O	2029	2037	mediated
O	2038	2045	effects
O	2045	2046	.

O	2047	2052	Based
O	2053	2055	on
O	2056	2064	findings
O	2065	2069	from
O	2070	2076	others
O	2076	2077	,
O	2078	2082	this
O	2083	2086	SNP
O	2087	2090	may
O	2091	2102	potentially
O	2103	2110	enhance
O	2111	2120	treatment
O	2121	2130	adherence
O	2131	2134	and
O	2135	2144	treatment
O	2145	2153	efficacy
O	2153	2154	.

O	2155	2157	We
O	2158	2162	plan
O	2163	2165	to
O	2166	2174	evaluate
O	2175	2178	the
O	2179	2187	clinical
O	2188	2194	impact
O	2195	2197	of
O	2198	2202	this
O	2203	2215	polymorphism
O	2216	2222	during
O	2223	2227	time
O	2227	2228	,
O	2229	2236	pending
O	2237	2247	sufficient
O	2248	2254	median
O	2255	2261	follow
O	2262	2264	up
O	2264	2265	.

O	2266	2280	ClinicalTrials
O	2280	2281	.
O	2281	2284	gov
O	2285	2296	NCT00066703
O	2296	2297	,
O	2298	2308	registered
O	2309	2315	August
O	2316	2317	6
O	2317	2318	,
O	2319	2323	2003
O	2323	2324	.
